FDA Modernization Act 3.0

Enumerated powers · passes

The bill directs the FDA, an agency within the executive branch, to implement a provision of the Consolidated Appropriations Act of 2023. This falls within Congress's enumerated power under Article I, Section 8, Clause 3 (the Commerce Clause) to regulate interstate and foreign commerce in drugs. The FDA's authority over new drug applications is a well-established exercise of this power. The bill does not create new regulatory authority but merely requires the FDA to update its regulations to align with existing statutory language.

Bill of Rights · passes

The bill does not implicate any of the first ten amendments. It does not restrict speech, religion, assembly, press, petition, the right to bear arms, quartering of soldiers, search and seizure, self-incrimination, due process, takings, fair trial, jury trial, or cruel and unusual punishment. It is a purely administrative rulemaking requirement.

Individual liberty · passes

The bill does not restrict individual liberty or property rights. It does not impose new obligations on individuals; rather, it directs the FDA to update its internal regulations. The change from animal testing to nonclinical alternatives does not restrict individual freedom but may actually reduce regulatory burdens on drug developers. There is no compelling constitutional issue here.

Decentralization · passes

The bill concerns the regulation of new drugs, which is inherently a national matter due to the interstate nature of drug development and marketing. An individual, family, or local community cannot effectively regulate the safety and efficacy of drugs that cross state lines. A state could theoretically regulate drugs, but a patchwork of state regulations would burden interstate commerce and create inefficiencies. The federal government has the minimum necessary role here, and the bill does not consolidate decision-making at a higher level than necessary; it merely directs the FDA to implement existing law.

Due process and takings · passes

The bill does not bypass due process or take property without just compensation. It requires the FDA to publish an interim final rule, which is a standard administrative procedure that includes notice and comment (even if post-promulgation). The rule does not deprive any person of life, liberty, or property without due process. It does not involve any taking of private property for public use.